ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Lycia Therapeutics
30.00
+12.00
66.67%
盤後:
26.50
-3.5000
-11.67%
19:59 EDT
成交量:
228.72萬
成交額:
6,325.94萬
市值:
15.63億
市盈率:
- -
高:
36.49
開:
28.55
低:
22.19
收:
18.00
52周最高:
36.49
52周最低:
22.19
股本:
5,209.46萬
流通股本:
1,470.00萬
量比:
- -
換手率:
15.56%
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
-11.83
市盈率(LYR):
- -
資料載入中...
總覽
公司
新聞資訊
公告
概念
沒有相關數據
資金流向
資金流入:
資金流出:
實時
日
周
月
季度
年
新聞資訊
別隻盯着 Anthropic:生物科技公司正悄然主導 IPO 市場
老虎资讯综合
·
6小時前
美股異動 | 生物科技公司Lycia Therapeutics(LYCA.US)登陸美股市場 股價升逾32%
智通财经
·
昨天
Lycia Therapeutics在將IPO規模擴大至3.175億美元后,即將登陸納斯達克,股價有望飆升
路透中文
·
10/23
過敏及自免生物技術公司Lycia Therapeutics(LYCA.US)今晚登陸納斯達克!IPO定價18美元/股 擬募資3.175億美元
智通财经
·
10/23
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/LYCA"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LYCA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LYCA\",,,,,undefined,":{"symbol":"LYCA","market":"US","secType":"STK","nameCN":"Lycia Therapeutics","latestPrice":30,"timestamp":1792785600000,"preClose":18,"halted":0,"volume":2287202,"hourTrading":{"tag":"盘后","latestPrice":26.5,"preClose":30,"latestTime":"19:59 EDT","volume":21598,"amount":605931.297,"timestamp":1792799969687,"change":-3.5,"changeRate":-0.116667,"amplitude":0.116667},"delay":0,"changeRate":0.6666666666666666,"floatShares":14700000,"shares":52094559,"eps":0,"marketStatus":"休市中","change":12,"latestTime":"10-23 16:00:00 EDT","open":28.55,"high":36.4931,"low":22.19,"amount":63259421.47999,"amplitude":0.794617,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"listingDate":1792728000000,"exchange":"NASDAQ","adjPreClose":18,"postHourTrading":{"tag":"盘后","latestPrice":26.5,"preClose":30,"latestTime":"19:59 EDT","volume":21598,"amount":605931.297,"timestamp":1792799969687,"change":-3.5,"changeRate":-0.116667,"amplitude":0.116667},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LYCA\",,,,,undefined,":{"symbol":"LYCA","floatShares":14700000,"roa":"--","roe":"--","lyrEps":0,"shares":52094559,"dividePrice":0,"high":36.4931,"amplitude":0.794617,"preClose":18,"low":22.19,"week52Low":22.19,"pbRate":"-11.83","psRate":"352.39","week52High":36.4931,"institutionHeld":0,"latestPrice":30,"eps":0,"divideRate":0,"volume":2287202,"delay":0,"ttmEps":0,"open":28.55,"prevYearClose":18,"prevWeekClose":18,"prevMonthClose":18,"prevQuarterClose":18,"fiveDayClose":18,"twentyDayClose":18,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LYCA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LYCA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LYCA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LYCA\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1157759837","title":"別隻盯着 Anthropic:生物科技公司正悄然主導 IPO 市場","url":"https://stock-news.laohu8.com/highlight/detail?id=1157759837","media":"老虎资讯综合","labels":["EditorSelect"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157759837?lang=zh_tw&edition=fundamental","pubTime":"2026-10-25 11:17","pubTimestamp":1792898274,"startTime":"0","endTime":"0","summary":"City Therapeutics 于 10 月 16 日上市首日上涨近 30%,尽管此时整体市场表现疲弱。史密斯表示,许多公司更倾向于暂时观望,因为大多数拟上市企业都在等待当前市场波动结束、美国中期选举过去,以及 Anthropic 完成 IPO 之后再采取行动。《华尔街日报》报道称,一份 Anthropic IPO 申报文件草案显示,该公司在 2026 年上半年亏损超过 800 亿美元。不过,就目前而言,生物科技投资者似乎并没有受到 IPO 市场低迷的影响。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"EditorSelect","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPO002","IAM","TRXB","RTSN","LYCA","CTY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2677979350","title":"美股異動 | 生物科技公司Lycia Therapeutics(LYCA.US)登陸美股市場 股價升逾32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677979350","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677979350?lang=zh_tw&edition=fundamental","pubTime":"2026-10-24 00:27","pubTimestamp":1792772851,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周五,专注于过敏和自身免疫性疾病治疗的生物科技公司Lycia Therapeutics(LYCA.US)登陆美股市场,开盘后股价涨超32%,报23.9美元。IPO价格为18美元。Lycia Therapeutics致力于开发旨在降解致病细胞外蛋白的疗法,初期聚焦自身免疫、炎症和过敏性疾病。其技术平台名为LYTAC(溶酶体靶向嵌合体),基于诺贝尔奖得主Carolyn Bertozzi在斯坦福大学的研究工作。其主要候选药物LCA-0061旨在降解免疫球蛋白E(IgE),用于治疗包括食物过敏在内的过敏性疾病,目前处于一期临床试验阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HBImain","BK4539","MEDX","LYCA","159837","LENZ","LNGR","XBI","SYNB","BK4139","GDOC","IBBJ","BK4588","AGNG","BK4585","BK4581","IEIH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677975556","title":"Lycia Therapeutics在將IPO規模擴大至3.175億美元后,即將登陸納斯達克,股價有望飆升","url":"https://stock-news.laohu8.com/highlight/detail?id=2677975556","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677975556?lang=zh_tw&edition=fundamental","pubTime":"2026-10-23 23:02","pubTimestamp":1792767764,"startTime":"0","endTime":"0","summary":"BUZZ-Lycia Therapeutics在将IPO规模扩大至3.175亿美元后,即将登陆纳斯达克,股价有望飙升10月23日-** 利西亚治疗公司(Lycia Therapeutics,股票代码:LYCA.O)在将美国首次公开募股(IPO)规模扩大至3.175亿美元后,预计将在纳斯达克上市首日高开** 这家药物研发公司预计开盘价为每股20美元,高于18美元的IPO发行价 (link)** 总部","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nL4S4691CW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","EVR","LYCA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677919112","title":"過敏及自免生物技術公司Lycia Therapeutics(LYCA.US)今晚登陸納斯達克!IPO定價18美元/股 擬募資3.175億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677919112","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677919112?lang=zh_tw&edition=fundamental","pubTime":"2026-10-23 10:34","pubTimestamp":1792722852,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LYCA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/LYCA\",params:#limit:6,delay:false,,,undefined,":[]}}